<img alt="" height="1" width="1" />AMRI selects compound for advanced preclinical testing in treatment of IBSNews-Medical.netAMRI (NASDAQ: AMRI) today announced the selection of a compound from its proprietary research program for the treatment of irritable bowel syndrome (IBS) ...<nobr></nobr> |